ABRAXANE[R] in Combination with Gemcitabine Increases Survival in First-Line Treatment of Advanced Pancreatic Cancer in Phase I/II Study.
Business Wire › April 18, 2010
Linked as:
Extract
ABRAXANE[R] in Combination with Gemcitabine Increases Survival in First-Line Treatment of Advanced Pancreatic Cancer in Phase I/II Study.
* Patients Receiving 125mg/m(2) ABRAXANE in Combination with Gemcitabine Demonstrated:
* Median Survival of 12.2 Months * 50 Percent Response Rate * 68 Percent Disease Control * Decrease in CA19-9 Tumor Biomarker Levels in 100 Percent of Patients Treated LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced updated overall survival findings from a phase I/II study of nab([R])-paclitaxel (ABRAXANE([R]) for Injectable Suspension) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with gemcitabine, demonstrated increased survival of the first-line t...See the full content of this document
Sponsored links
